size 12
Title: A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
Phase: III
Leading organization:NuCana plc
Current Trial Status Date:2019-12-24

Title: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Phase: III
Leading organization:Alliance for Clinical Trials in Oncology
Current Trial Status Date:2021-01-06

Title: A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Phase: III
Leading organization:Epizyme, Inc.
Current Trial Status Date:2019-12-19

Title: An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase: III
Leading organization:NRG Oncology
Current Trial Status Date:2021-06-14

Title: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)
Phase: III
Leading organization:Allovir
Current Trial Status Date:2021-01-06

Title: Phase III Trial of Immunotherapy-Based Combination Therapy with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Phase: III
Leading organization:SWOG
Current Trial Status Date:2020-11-16

Title: An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies
Phase: III
Leading organization:Agios Pharmaceuticals
Current Trial Status Date:2021-01-28

Title: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Phase: III
Leading organization:Alliance for Clinical Trials in Oncology
Current Trial Status Date:2020-06-03

Title: A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Phase: III
Leading organization:Children's Oncology Group
Current Trial Status Date:2020-07-20

Title: A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer
Phase: III
Leading organization:Blue Earth Diagnostics
Current Trial Status Date:2021-03-08

Title: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Phase: III
Leading organization:SWOG
Current Trial Status Date:2020-12-14

Title: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors
Phase: III
Leading organization:Bristol-Myers Squibb
Current Trial Status Date:2020-10-15
